Šw‰ï”•\
Inatani M, Iwasaki K, Komori R, Arimura S, Takamura Y.
Intraocular Pressure-Lowering Effect of Intraocular Lens Refixation in Patients with Elevated Intraocular Pressure Due to Intraocular Lens Subluxation
The 40th APAO Congress, Delhi, India April 3-6, 2025
Intraocular Pressure-Lowering Effect of Intraocular Lens Refixation in Patients with Elevated Intraocular Pressure Due to Intraocular Lens Subluxation
The 40th APAO Congress, Delhi, India April 3-6, 2025
Takamura Y
Efficacy of Vitrectomy for Diabetic Macular Edema: One-Year Follow-Up Multi-Center Study in Japan
TOA 59th National Congress, Antalya, Turkey, Nov 19-25, 2025
Efficacy of Vitrectomy for Diabetic Macular Edema: One-Year Follow-Up Multi-Center Study in Japan
TOA 59th National Congress, Antalya, Turkey, Nov 19-25, 2025
TMatsumura T, Arimura S, Iwasaki K, Suzuki M, Takamura Y, Inatani M
Changes in ocular higher-order aberrations and corneal backward light scattering after instillation of brimonidine/brinzolamide versus@brimonidine/timolol: a randomized, double-masked, crossover clinical trial
ARVO 2025, Salt Lake City, Utah, USA May 4-8, 2025
Changes in ocular higher-order aberrations and corneal backward light scattering after instillation of brimonidine/brinzolamide versus@brimonidine/timolol: a randomized, double-masked, crossover clinical trial
ARVO 2025, Salt Lake City, Utah, USA May 4-8, 2025
Arimura S, Iwasaki K, Suzuki M, Inatani M
A Deep Learning Model for Detecting the Eyes Receiving Glaucoma Medications Using Anterior Segment Images
ARVO 2025, Salt Lake City, Utah, USA May 4-8, 2025
A Deep Learning Model for Detecting the Eyes Receiving Glaucoma Medications Using Anterior Segment Images
ARVO 2025, Salt Lake City, Utah, USA May 4-8, 2025
Iwasaki K, Arimura S, Inatani M
Intraocular Pressure-Lowering Effect of Intraocular Lens Refixation in Patients with Elevated Intraocular Pressure Due to Intraocular Lens Subluxation
ARVO 2025, Salt Lake City, Utah, USA May 4-8, 2025
Intraocular Pressure-Lowering Effect of Intraocular Lens Refixation in Patients with Elevated Intraocular Pressure Due to Intraocular Lens Subluxation
ARVO 2025, Salt Lake City, Utah, USA May 4-8, 2025
Inatani M, Kohama I, Chu A.
Surgical outcomes analyzed with AAO MIGS success criteria from a Japan postmarket surveillance of iStent inject® W combined with phacoemulsification
11th World Glaucoma Congress, Honolulu, Hawaii, USA, June 25-28, 2025
Surgical outcomes analyzed with AAO MIGS success criteria from a Japan postmarket surveillance of iStent inject® W combined with phacoemulsification
11th World Glaucoma Congress, Honolulu, Hawaii, USA, June 25-28, 2025
Iwasaki K, Arimura S, Inatani M
Intraocular Pressure-Lowering Effect of Intraocular Lens Refixation in Patients with Elevated Intraocular Pressure Due to Intraocular Lens Subluxation
The 18th Joint Meeting of China-Japan-Korea Ophthalmologists, Hangzhou International Expo Center, Hangzhou, China Sep 6, 2025
Intraocular Pressure-Lowering Effect of Intraocular Lens Refixation in Patients with Elevated Intraocular Pressure Due to Intraocular Lens Subluxation
The 18th Joint Meeting of China-Japan-Korea Ophthalmologists, Hangzhou International Expo Center, Hangzhou, China Sep 6, 2025
Yamada Y, Takamura Y, Inatani M, J-CREST Group
Efficacy of Vitrectomy for Diabetic Macular Edema: One-Year Follow-Up Multi-Center Study in Japan
The 5th Asia Retina Congress, Taipei, Taiwan, Oct 25-26, 2025
Efficacy of Vitrectomy for Diabetic Macular Edema: One-Year Follow-Up Multi-Center Study in Japan
The 5th Asia Retina Congress, Taipei, Taiwan, Oct 25-26, 2025
Inatani M, Chan P, Choi W, Yip V, Rehn A, Chu A.
Postoperative Complications of iStent inject Combined with Phacoemulsification in Asian Eyes with Glaucoma: Findings From a Systematic Review and Meta-Analysis
The 41th APAO Congress, Hong Kong, China, Feb 5-8, 2026
Postoperative Complications of iStent inject Combined with Phacoemulsification in Asian Eyes with Glaucoma: Findings From a Systematic Review and Meta-Analysis
The 41th APAO Congress, Hong Kong, China, Feb 5-8, 2026
îà‘º@‰ÀO
“œ”A•aŠá‡•¹Ç гŽÒƒtƒ@[ƒXƒg‚ÉŠî‚Âŗǂ̎¡—Ãí—ª‚ÌŠm—§‚ð‚ß‚´‚µ‚Ä
‘æ129‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@
—ߘa7”N4ŒŽ17-20“ú@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
“œ”A•aŠá‡•¹Ç гŽÒƒtƒ@[ƒXƒg‚ÉŠî‚Âŗǂ̎¡—Ãí—ª‚ÌŠm—§‚ð‚ß‚´‚µ‚Ä
‘æ129‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@
—ߘa7”N4ŒŽ17-20“ú@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
ˆî’J@‘å
”’“àáŽèp•¹—pŠá“àƒhƒŒ[ƒ“(iStent‚ÆHydrus)
‘æ40‰ñJSCRSŠwp‘‰ï@‹³ˆçƒZƒ~ƒi[ ”’“àáŽèp‚ÆMIGS
—ߘa7”N6ŒŽ20-22“ú@•Ÿ‰ª‘Û‰ï‹cê
”’“àáŽèp•¹—pŠá“àƒhƒŒ[ƒ“(iStent‚ÆHydrus)
‘æ40‰ñJSCRSŠwp‘‰ï@‹³ˆçƒZƒ~ƒi[ ”’“àáŽèp‚ÆMIGS
—ߘa7”N6ŒŽ20-22“ú@•Ÿ‰ª‘Û‰ï‹cê
—L‘º@®Œå
lH’m”\‚É‚æ‚é‰ÂŽ‹‰»‚ÉŠî‚—Γàá‚Ì’è‹`
‘æ36‰ñ“ú–{—ΓàáŠw‰ï@ƒVƒ“ƒ|ƒWƒEƒ€1
—ߘa7”N9ŒŽ12-14“ú@_ŒËƒ|[ƒgƒsƒAƒzƒeƒ‹
lH’m”\‚É‚æ‚é‰ÂŽ‹‰»‚ÉŠî‚—Γàá‚Ì’è‹`
‘æ36‰ñ“ú–{—ΓàáŠw‰ï@ƒVƒ“ƒ|ƒWƒEƒ€1
—ߘa7”N9ŒŽ12-14“ú@_ŒËƒ|[ƒgƒsƒAƒzƒeƒ‹
Šâí•@Œ’‘¾˜Y
—Ž‹û—Γàá‚ɑ΂·‚éàh‰ßŽèp‚ÌŒø‰Ê‚Ɖۑè
‘æ36‰ñ“ú–{—ΓàáŠw‰ï@ƒVƒ“ƒ|ƒWƒEƒ€4
—ߘa7”N9ŒŽ12-14“ú@_ŒËƒ|[ƒgƒsƒAƒzƒeƒ‹
—Ž‹û—Γàá‚ɑ΂·‚éàh‰ßŽèp‚ÌŒø‰Ê‚Ɖۑè
‘æ36‰ñ“ú–{—ΓàáŠw‰ï@ƒVƒ“ƒ|ƒWƒEƒ€4
—ߘa7”N9ŒŽ12-14“ú@_ŒËƒ|[ƒgƒsƒAƒzƒeƒ‹
îà‘º@‰ÀO
—ߘa‚Ì“œ”A•a–Ô–ŒÇƒŒ[ƒU[Ž¡—Ã@`–Ô–ŒƒŒ[ƒU[‚ðÄl‚µ‚悤`@–ò•¨Ž¡—ÂƂ̕¹—p
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒXiƒIƒ“ƒfƒ}ƒ“ƒhj
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
—ߘa‚Ì“œ”A•a–Ô–ŒÇƒŒ[ƒU[Ž¡—Ã@`–Ô–ŒƒŒ[ƒU[‚ðÄl‚µ‚悤`@–ò•¨Ž¡—ÂƂ̕¹—p
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒXiƒIƒ“ƒfƒ}ƒ“ƒhj
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
Šâí•@Œ’‘¾˜Y
“«—ΓàáŽèp@¬Œ÷—¦‚ðã‚°‚é‚É‚ÍH
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒVƒ“ƒ|ƒWƒEƒ€
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
“«—ΓàáŽèp@¬Œ÷—¦‚ðã‚°‚é‚É‚ÍH
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒVƒ“ƒ|ƒWƒEƒ€
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
îà‘º@‰ÀO
“à‰Èˆã–Úü‚Ì“œ”A•a–Ô–ŒÇE‰©”Á•‚Žî‚̉摜ŒŸ¸
‘æ32‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@‹³ˆçƒZƒ~ƒi[
—ߘa8”N1ŒŽ16-17“ú@ƒpƒVƒtƒBƒR‰¡•l
“à‰Èˆã–Úü‚Ì“œ”A•a–Ô–ŒÇE‰©”Á•‚Žî‚̉摜ŒŸ¸
‘æ32‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@‹³ˆçƒZƒ~ƒi[
—ߘa8”N1ŒŽ16-17“ú@ƒpƒVƒtƒBƒR‰¡•l
‘哈@GKA‚‘º@‰ÀO
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚ésodium glucose co-transporter 2‘jŠQ–ò‚̉e‹¿
‘æ32‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@ƒVƒ“ƒ|ƒWƒEƒ€4
—ߘa8”N1ŒŽ16-17“ú@ƒpƒVƒtƒBƒR‰¡•l
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚ésodium glucose co-transporter 2‘jŠQ–ò‚̉e‹¿
‘æ32‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@ƒVƒ“ƒ|ƒWƒEƒ€4
—ߘa8”N1ŒŽ16-17“ú@ƒpƒVƒtƒBƒR‰¡•l
¼‘º@Œ’‘å
Šp–ŒˆÚA‚ÌŠî–{@Šp–ŒˆÚA‚ÌpŒãŠÇ—
‘æ49‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï@‹³ˆçƒZƒ~ƒi[
—ߘa8”N1ŒŽ30“ú-2ŒŽ1“ú@•Ÿ‰ª‘Û‰ï‹cêAƒ}ƒŠƒ“ƒƒbƒZ•Ÿ‰ªBŠÙ
Šp–ŒˆÚA‚ÌŠî–{@Šp–ŒˆÚA‚ÌpŒãŠÇ—
‘æ49‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï@‹³ˆçƒZƒ~ƒi[
—ߘa8”N1ŒŽ30“ú-2ŒŽ1“ú@•Ÿ‰ª‘Û‰ï‹cêAƒ}ƒŠƒ“ƒƒbƒZ•Ÿ‰ªBŠÙ
îà‘º@‰ÀO
“œ”A•a–Ô–ŒÇf—ÂÌi‰»‚ÆŠá‰È˜AŒg‚Ì[‰»
‘æ60‰ñ“œ”A•aŠw‚Ìi•à@‹³ˆçƒZƒ~ƒi[
—ߘa8”N3ŒŽ27-28“ú@ŠâŽèŒ§·‰ªŽs
“œ”A•a–Ô–ŒÇf—ÂÌi‰»‚ÆŠá‰È˜AŒg‚Ì[‰»
‘æ60‰ñ“œ”A•aŠw‚Ìi•à@‹³ˆçƒZƒ~ƒi[
—ߘa8”N3ŒŽ27-28“ú@ŠâŽèŒ§·‰ªŽs
ˆî’J@‘å
ƒŠƒAƒ‹ƒ[ƒ‹ƒhƒf[ƒ^‚©‚瓾‚ç‚ꂽiStent inject W‚Ì’·ŠúˆÀ‘S«‚Æ—LŒø«
Earlier surgical intervention in glaucoma treatment -—ΓàᎡ—ÑŠúŽèp‰î“ü‚̉”\«- Vol.2
‘æ129‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@ƒOƒ‰ƒEƒRƒX ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa7”N4ŒŽ17-20“ú@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
ƒŠƒAƒ‹ƒ[ƒ‹ƒhƒf[ƒ^‚©‚瓾‚ç‚ꂽiStent inject W‚Ì’·ŠúˆÀ‘S«‚Æ—LŒø«
Earlier surgical intervention in glaucoma treatment -—ΓàᎡ—ÑŠúŽèp‰î“ü‚̉”\«- Vol.2
‘æ129‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@ƒOƒ‰ƒEƒRƒX ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa7”N4ŒŽ17-20“ú@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
ˆî’J@‘å
—ΓàápŒã‚Ì”º‘–Žx‰‡
‘æ36‰ñ“ú–{—ΓàáŠw‰ï@‘å’Ë»–òƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
—ߘa7”N9ŒŽ12-14“ú@_ŒËƒ|[ƒgƒsƒAƒzƒeƒ‹
—ΓàápŒã‚Ì”º‘–Žx‰‡
‘æ36‰ñ“ú–{—ΓàáŠw‰ï@‘å’Ë»–òƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
—ߘa7”N9ŒŽ12-14“ú@_ŒËƒ|[ƒgƒsƒAƒzƒeƒ‹
ˆî’J@‘å
—Õ°Œ¤‹†‚©‚ç‚Ý‚¦‚éV‚µ‚¢‰Â”\«
‚±‚ê‚©‚ç‚̗ΓàᎡ—Âðl‚¦‚é〜–ò•¨Ž¡—Â̒m“IDŠïS〜
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ŽQ“V»–òƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
—Õ°Œ¤‹†‚©‚ç‚Ý‚¦‚éV‚µ‚¢‰Â”\«
‚±‚ê‚©‚ç‚̗ΓàᎡ—Âðl‚¦‚é〜–ò•¨Ž¡—Â̒m“IDŠïS〜
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ŽQ“V»–òƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
ˆî’J@‘å
‘S•ûˆÊŒ^”z‡“_Šá–òƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë
Žå—¬o˜H‚©‚ç‚Ì–[…—¬o‚ðl‚¦‚é
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@‹»˜aДޮ‰ïŽÐƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
‘S•ûˆÊŒ^”z‡“_Šá–òƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë
Žå—¬o˜H‚©‚ç‚Ì–[…—¬o‚ðl‚¦‚é
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@‹»˜aДޮ‰ïŽÐƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
ˆî’J@‘å
’ʉ@Œp‘±—¦‚©‚çl‚¦‚é—ΓàᎡ—Ãí—ª
‘Šú—Γàá‚ւ̃Aƒvƒ[ƒ`〜”’“àáŽèp•¹—pŠá“àƒhƒŒ[ƒ“〜Vol.5
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒOƒ‰ƒEƒRƒXEƒWƒƒƒpƒ“ ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
’ʉ@Œp‘±—¦‚©‚çl‚¦‚é—ΓàᎡ—Ãí—ª
‘Šú—Γàá‚ւ̃Aƒvƒ[ƒ`〜”’“àáŽèp•¹—pŠá“àƒhƒŒ[ƒ“〜Vol.5
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒOƒ‰ƒEƒRƒXEƒWƒƒƒpƒ“ ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
ˆî’J@‘å
Ž¡—ÑI‘ð@–ò•¨HŽèpH‚Ç‚¤‘I‚ÔH
‚¢‚Ü‚³‚ç•·‚¯‚È‚¢—Γàá2025‚Ç‚¤ƒAƒvƒ[ƒ`‚·‚éHÅ“K‚ÈŽ¡—Ãí—ª‚ւ̃Xƒeƒbƒv
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@çŽõ»–òƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
Ž¡—ÑI‘ð@–ò•¨HŽèpH‚Ç‚¤‘I‚ÔH
‚¢‚Ü‚³‚ç•·‚¯‚È‚¢—Γàá2025‚Ç‚¤ƒAƒvƒ[ƒ`‚·‚éHÅ“K‚ÈŽ¡—Ãí—ª‚ւ̃Xƒeƒbƒv
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@çŽõ»–òƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
îà‘º@‰ÀO
ƒGƒrƒfƒ“ƒX‚Å‘ñ‚AuDMEvгŽÒ‚³‚ñ‚ÌgŽ‹h—ˆ
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
ƒGƒrƒfƒ“ƒX‚Å‘ñ‚AuDMEvгŽÒ‚³‚ñ‚ÌgŽ‹h—ˆ
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêEƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
îà‘º@‰ÀO
ƒoƒr[ƒXƒ‚‚Ì‘ŠúŽ¡—Éî“ü‚Å‘_‚¤DME“‰»‚̉ñ”ð
‘æ64‰ñ“ú–{–Ô–ŒÉŽq‘ÌŠw‰ï‘‰ï@’†ŠO»–ò@ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
—ߘa7”N12ŒŽ5-7“ú@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
ƒoƒr[ƒXƒ‚‚Ì‘ŠúŽ¡—Éî“ü‚Å‘_‚¤DME“‰»‚̉ñ”ð
‘æ64‰ñ“ú–{–Ô–ŒÉŽq‘ÌŠw‰ï‘‰ï@’†ŠO»–ò@ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
—ߘa7”N12ŒŽ5-7“ú@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
™Œ´@—F‰À
•Ÿˆä‘åŠwˆãŠw•”•‘®•a‰@‚É‚¨‚¢‚Ä”’ñ•àsŒP—û‚ðŽó‚¯‚½Š³ŽÒ‚ÌŽÀ‘Ô’²¸
‘æ26‰ñ“ú–{ƒ[ƒrƒWƒ‡ƒ“Šw‰ïŠwp‘‰ï@
—ߘa7”N5ŒŽ23-25“ú@L“‡‘Û‰ï‹cê
•Ÿˆä‘åŠwˆãŠw•”•‘®•a‰@‚É‚¨‚¢‚Ä”’ñ•àsŒP—û‚ðŽó‚¯‚½Š³ŽÒ‚ÌŽÀ‘Ô’²¸
‘æ26‰ñ“ú–{ƒ[ƒrƒWƒ‡ƒ“Šw‰ïŠwp‘‰ï@
—ߘa7”N5ŒŽ23-25“ú@L“‡‘Û‰ï‹cê
’Ò@ç—zA’Ò@—²G
ƒoƒ‹ƒvƒŽ_‘Ù“à“Š—^ƒ}ƒEƒX‚Ö‚ÌŒoŒûƒJƒ‹ƒmƒVƒ““Š—^‚É‚æ‚éŽÐ‰ï«‰ü‘PŒø‰Ê‚̉ðÍ
‘æ68‰ñ“ú–{_Œo‰»Šw‰ï‘å‰ï
—ߘa7”N9ŒŽ11-13“ú@ƒEƒBƒ“ƒN‚ ‚¢‚¿
ƒoƒ‹ƒvƒŽ_‘Ù“à“Š—^ƒ}ƒEƒX‚Ö‚ÌŒoŒûƒJƒ‹ƒmƒVƒ““Š—^‚É‚æ‚éŽÐ‰ï«‰ü‘PŒø‰Ê‚̉ðÍ
‘æ68‰ñ“ú–{_Œo‰»Šw‰ï‘å‰ï
—ߘa7”N9ŒŽ11-13“ú@ƒEƒBƒ“ƒN‚ ‚¢‚¿
Inatani M, Tone Y, Ikeda T, Angeles R
Sepetaprost alone and in combination with timolol in a long-term study (ANGEL-J2)
‘æ36‰ñ“ú–{—ΓàáŠw‰ï@
—ߘa7”N9ŒŽ12-14“ú@_ŒËƒ|[ƒgƒsƒAƒzƒeƒ‹
Sepetaprost alone and in combination with timolol in a long-term study (ANGEL-J2)
‘æ36‰ñ“ú–{—ΓàáŠw‰ï@
—ߘa7”N9ŒŽ12-14“ú@_ŒËƒ|[ƒgƒsƒAƒzƒeƒ‹
ˆî’J@‘å
ƒxƒ“ƒUƒ‹ƒRƒjƒEƒ€”ñŠÜ—L‹y‚ÑŠÜ—LƒuƒŠƒ‚ƒjƒWƒ“/ƒ`ƒ‚ƒ[ƒ‹”z‡“_Šá‰t‚Ì”äŠrŽŽŒ±
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêAƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
ƒxƒ“ƒUƒ‹ƒRƒjƒEƒ€”ñŠÜ—L‹y‚ÑŠÜ—LƒuƒŠƒ‚ƒjƒWƒ“/ƒ`ƒ‚ƒ[ƒ‹”z‡“_Šá‰t‚Ì”äŠrŽŽŒ±
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêAƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
îà‘º‰ÀOAYongsoo Kim
‘B“œ”A•a–Ô–ŒÇ‚ɑ΂·‚éƒuƒƒ‹ƒVƒYƒ}ƒ‹FCONDORŽŽŒ±54T‚Ì“ú–{lƒTƒuƒOƒ‹[ƒv‰ðÍ
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêAƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
‘B“œ”A•a–Ô–ŒÇ‚ɑ΂·‚éƒuƒƒ‹ƒVƒYƒ}ƒ‹FCONDORŽŽŒ±54T‚Ì“ú–{lƒTƒuƒOƒ‹[ƒv‰ðÍ
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêAƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
—L‘º@®Œå
lH’m”\‚ª’–Ú‚·‚éŠá’ê\‘¢‚ÉŠî‚—Γàá‚ÌV‚½‚ÈŽ‹Šo“I‰ðŽß
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêAƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
lH’m”\‚ª’–Ú‚·‚éŠá’ê\‘¢‚ÉŠî‚—Γàá‚ÌV‚½‚ÈŽ‹Šo“I‰ðŽß
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêAƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
Šâ핌’‘¾˜YA—L‘º®ŒåA‚‘º‰ÀOAˆî’J‘å
—ΓàáŽèpšnD’²¸2024
Clinical Practice Preferences for Glaucoma Surgery in Japan in 2024
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêAƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
—ΓàáŽèpšnD’²¸2024
Clinical Practice Preferences for Glaucoma Surgery in Japan in 2024
‘æ79‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa7”N10ŒŽ9-12“ú@‘åã‘Û‰ï‹cêAƒŠ[ƒKƒƒCƒ„ƒ‹ƒzƒeƒ‹‘åã
’Ò—²GAˆî’J‘å
‰ß‹Ž13”NŠÔ‚É•Ÿˆä‘åŠwŠá‰È‚ÅŒoŒ±‚µ‚½•@«Ž‹_ŒoÇ11—á‚ÌŒŸ“¢
‘æ63‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï
—ߘa7”N11ŒŽ21-22“ú@ç—¢ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXƒZƒ“ƒ^[
‰ß‹Ž13”NŠÔ‚É•Ÿˆä‘åŠwŠá‰È‚ÅŒoŒ±‚µ‚½•@«Ž‹_ŒoÇ11—á‚ÌŒŸ“¢
‘æ63‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï
—ߘa7”N11ŒŽ21-22“ú@ç—¢ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXƒZƒ“ƒ^[
ŽR“c—Y‹MAáÁ“c˜Ð‹GA‚‘º‰ÀOA‘哈GKAŒã‘ò½Aˆî’J‘å
‹ÇŠ«“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚钼ڋÌłÆFaricimab“Š—^‚̇˜‚Ì—DˆÊ«
‘æ32‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa8”N1ŒŽ16-17“ú@ƒpƒVƒtƒBƒR‰¡•l
‹ÇŠ«“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚钼ڋÌłÆFaricimab“Š—^‚̇˜‚Ì—DˆÊ«
‘æ32‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa8”N1ŒŽ16-17“ú@ƒpƒVƒtƒBƒR‰¡•l
áÁ“c˜Ð‹GA‚‘º‰ÀOAŽR“c—Y‹MA¡–ìˆÇ”üA•½–ì—²—YA–ìè”ü•äAˆî’J‘å
RVEGF–òŽ¡—ÃŒã‚É’¾Ã‰»‚µ‚½“œ”A•a‰©”Á•‚Žî‚É‚¨‚¯‚é–³ŒŒŠÇ—Ìˆæ‚ÆŽ‹–슴“x‚Æ‚Ì‘ŠŠÖ
‘æ32‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa8”N1ŒŽ16-17“ú@ƒpƒVƒtƒBƒR‰¡•l
RVEGF–òŽ¡—ÃŒã‚É’¾Ã‰»‚µ‚½“œ”A•a‰©”Á•‚Žî‚É‚¨‚¯‚é–³ŒŒŠÇ—Ìˆæ‚ÆŽ‹–슴“x‚Æ‚Ì‘ŠŠÖ
‘æ32‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa8”N1ŒŽ16-17“ú@ƒpƒVƒtƒBƒR‰¡•l
™Œ´@—F‰À
Žq‚Ç‚à‚½‚¿‚Ì–Ú‚ðŽç‚邽‚ß‚É
‘æ76‰ñ•ŸˆäŒ§¬Ž™•ÛŒ’‹¦‰ïŠwpW‰ï
—ߘa8”N2ŒŽ11“ú@@•ŸˆäŽs
Žq‚Ç‚à‚½‚¿‚Ì–Ú‚ðŽç‚邽‚ß‚É
‘æ76‰ñ•ŸˆäŒ§¬Ž™•ÛŒ’‹¦‰ïŠwpW‰ï
—ߘa8”N2ŒŽ11“ú@@•ŸˆäŽs
‚‘º@‰ÀO
“œ”A•a‚ÅŽ¸–¾‚µ‚È‚¢‚悤‚É`‹‚ß‚ç‚ê‚é“à‰È‚ÆŠá‰È‚̘AŒg`
Šá‰È~“œ”A•af—Èã@˜AŒg‚̉ï in TOYOTA
—ߘa7”N6ŒŽ4“ú@ˆ¤’mŒ§–L“cŽs
“œ”A•a‚ÅŽ¸–¾‚µ‚È‚¢‚悤‚É`‹‚ß‚ç‚ê‚é“à‰È‚ÆŠá‰È‚̘AŒg`
Šá‰È~“œ”A•af—Èã@˜AŒg‚̉ï in TOYOTA
—ߘa7”N6ŒŽ4“ú@ˆ¤’mŒ§–L“cŽs
ˆî’J@‘å
[‘wŠwKƒ‚ƒfƒ‹‚ŗΓàá“_ŠáŽ¡—Âð•ªÍ‚·‚éB
Mikeluna WEEK 2025`—ΓàᎡ—Âðl‚¦‚é`
—ߘa7”N6ŒŽ11“ú@•ŸˆäŽs‚©‚ç‘S‘WEB”zM
[‘wŠwKƒ‚ƒfƒ‹‚ŗΓàá“_ŠáŽ¡—Âð•ªÍ‚·‚éB
Mikeluna WEEK 2025`—ΓàᎡ—Âðl‚¦‚é`
—ߘa7”N6ŒŽ11“ú@•ŸˆäŽs‚©‚ç‘S‘WEB”zM
‚‘º@‰ÀO
“«DME‚ɑ΂·‚éƒtƒ@ƒŠƒVƒ}ƒu‚Ö‚ÌŠú‘Ò
–Ô–ŒŽ¾Š³‚ÌfŽ@‚ðl‚¦‚é‰ï`Ang-2‘jŠQˆÓ‹`‚É—§‚¿•Ô‚é`
—ߘa7”N6ŒŽ16“ú@‘åãŽs
“«DME‚ɑ΂·‚éƒtƒ@ƒŠƒVƒ}ƒu‚Ö‚ÌŠú‘Ò
–Ô–ŒŽ¾Š³‚ÌfŽ@‚ðl‚¦‚é‰ï`Ang-2‘jŠQˆÓ‹`‚É—§‚¿•Ô‚é`
—ߘa7”N6ŒŽ16“ú@‘åãŽs
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2025
AILAMIDE 5th Anniversary SENJU Live Web Sminar
—ߘa7”N7ŒŽ2“ú@•ŸˆäŽs‚©‚ç’†Žl‘‚ÖWeb”zM
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2025
AILAMIDE 5th Anniversary SENJU Live Web Sminar
—ߘa7”N7ŒŽ2“ú@•ŸˆäŽs‚©‚ç’†Žl‘‚ÖWeb”zM
’Ò@—²G@@
•Ÿˆä‘åŠwŠá‰È‚ł̎‹_Œo޾гf—Âɂ‚¢‚Ä
•ŸˆäŒ§Šá‰ÈE”]_Œo“à‰È‡“¯ƒZƒ~ƒi[
—ߘa7”N7ŒŽ17“ú@•ŸˆäŽs
•Ÿˆä‘åŠwŠá‰È‚ł̎‹_Œo޾гf—Âɂ‚¢‚Ä
•ŸˆäŒ§Šá‰ÈE”]_Œo“à‰È‡“¯ƒZƒ~ƒi[
—ߘa7”N7ŒŽ17“ú@•ŸˆäŽs
ˆî’J@‘å
—ΓàáŽèpŽ¡—à Up to date
—ΓàáŽèp‚ðl‚¦‚é‰ïin“Þ—Ç
—ߘa7”N7ŒŽ24“ú@“Þ—ÇŽs
—ΓàáŽèpŽ¡—à Up to date
—ΓàáŽèp‚ðl‚¦‚é‰ïin“Þ—Ç
—ߘa7”N7ŒŽ24“ú@“Þ—ÇŽs
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2025
‘æ27‰ñ‰«“êŠá޾гƒtƒH[ƒ‰ƒ€
—ߘa7”N7ŒŽ26“ú@‰«“ꌧ“ß”eŽs
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2025
‘æ27‰ñ‰«“êŠá޾гƒtƒH[ƒ‰ƒ€
—ߘa7”N7ŒŽ26“ú@‰«“ꌧ“ß”eŽs
‚‘º@‰ÀO
“œ”A•a‚ÅŽ¸–¾‚³‚¹‚È‚¢‚½‚ß‚É`‹‚ß‚ç‚ê‚é“à‰È‚ÆŠá‰È‚̘AŒg`
•ŸˆäŒ§“à‰Èˆã‰ïŠwpu‰‰‰ï
—ߘa7”N8ŒŽ2“ú@•ŸˆäŒ§ˆãŽt‰ïŠÙ
“œ”A•a‚ÅŽ¸–¾‚³‚¹‚È‚¢‚½‚ß‚É`‹‚ß‚ç‚ê‚é“à‰È‚ÆŠá‰È‚̘AŒg`
•ŸˆäŒ§“à‰Èˆã‰ïŠwpu‰‰‰ï
—ߘa7”N8ŒŽ2“ú@•ŸˆäŒ§ˆãŽt‰ïŠÙ
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2025
‘æ43‰ñ“¹–kŠá‰Èˆã‰ïW’k‰ï
—ߘa7”N8ŒŽ23“ú@–kŠC“¹ˆ®ìŽs
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2025
‘æ43‰ñ“¹–kŠá‰Èˆã‰ïW’k‰ï
—ߘa7”N8ŒŽ23“ú@–kŠC“¹ˆ®ìŽs
îà‘º@‰ÀO
“«DME‚ɑ΂·‚éƒoƒr[ƒXƒ‚‚Ö‚ÌŠú‘Ò
ƒoƒr[ƒXƒ‚””„3Žü”N‹L”Ou‰‰‰ï in –k‹ãB
—ߘa7”N8ŒŽ28“ú@•Ÿ‰ªŒ§
“«DME‚ɑ΂·‚éƒoƒr[ƒXƒ‚‚Ö‚ÌŠú‘Ò
ƒoƒr[ƒXƒ‚””„3Žü”N‹L”Ou‰‰‰ï in –k‹ãB
—ߘa7”N8ŒŽ28“ú@•Ÿ‰ªŒ§
îà‘º@‰ÀO
ƒoƒr[ƒXƒ‚‚Ì“Á«‚ð¶‚©‚µ‚½DMEŽ¡—Ã
HOT TOPICS Web seminar on ophthalmology
—ߘa7”N8ŒŽ29“ú@‘åãŽs‚©‚çWeb”zM
ƒoƒr[ƒXƒ‚‚Ì“Á«‚ð¶‚©‚µ‚½DMEŽ¡—Ã
HOT TOPICS Web seminar on ophthalmology
—ߘa7”N8ŒŽ29“ú@‘åãŽs‚©‚çWeb”zM
îà‘º@‰ÀO
гŽÒƒtƒ@[ƒXƒg‚ÌDMEŽ¡—Ã
Tokyo-bay Ophthalmic Seminar ~The Next Generations~
—ߘa7”N9ŒŽ3“ú@ç—tŒ§‰YˆÀŽs
гŽÒƒtƒ@[ƒXƒg‚ÌDMEŽ¡—Ã
Tokyo-bay Ophthalmic Seminar ~The Next Generations~
—ߘa7”N9ŒŽ3“ú@ç—tŒ§‰YˆÀŽs
îà‘º@‰ÀO
ƒxƒIƒrƒ…‚ª’˜Œø‚·‚éDMEÇ—á‚Ì“Á’¥‚ðl‚¦‚é
DMEŽ¡—Â̗հ’m`•a¨‚ðŒ©‹É‚ßAŽ‹—Í‚ðŽç‚é`
—ߘa7”N9ŒŽ8“ú@Web”zM
ƒxƒIƒrƒ…‚ª’˜Œø‚·‚éDMEÇ—á‚Ì“Á’¥‚ðl‚¦‚é
DMEŽ¡—Â̗հ’m`•a¨‚ðŒ©‹É‚ßAŽ‹—Í‚ðŽç‚é`
—ߘa7”N9ŒŽ8“ú@Web”zM
îà‘º@‰ÀO
“œ”A•a–Ô–ŒÇE‰©”Á•‚Žî‚ɑ΂·‚éSTTA Žè‹Z
‚í‚©‚à‚Æ»–òWebu‰‰‰ï
—ߘa7”N9ŒŽ19“ú@Web”zM
“œ”A•a–Ô–ŒÇE‰©”Á•‚Žî‚ɑ΂·‚éSTTA Žè‹Z
‚í‚©‚à‚Æ»–òWebu‰‰‰ï
—ߘa7”N9ŒŽ19“ú@Web”zM
îà‘º@‰ÀO
Œ¤‹†‚ðŠy‚µ‚ñ‚ł݂܂¹‚ñ‚©H`Ž„‚Ì•à‚ñ‚¾“œ”A•aŠá‡•¹Ç‚ÌŒ¤‹†`
‘æ107‰ñ“Œ‹žˆã‘åŠá‰È—Õ°§˜b‰ï
—ߘa7”N10ŒŽ4“ú@“Œ‹ž“s
Œ¤‹†‚ðŠy‚µ‚ñ‚ł݂܂¹‚ñ‚©H`Ž„‚Ì•à‚ñ‚¾“œ”A•aŠá‡•¹Ç‚ÌŒ¤‹†`
‘æ107‰ñ“Œ‹žˆã‘åŠá‰È—Õ°§˜b‰ï
—ߘa7”N10ŒŽ4“ú@“Œ‹ž“s
ˆî’J@‘å
‚܂Ƃ߂ĉðàI—Γàá“_Šá–ò2025
‘æ4‰ñ International Airport Ophthalmic Seminar
—ߘa7”N10ŒŽ25“ú@ç—tŒ§¬“cŽs
‚܂Ƃ߂ĉðàI—Γàá“_Šá–ò2025
‘æ4‰ñ International Airport Ophthalmic Seminar
—ߘa7”N10ŒŽ25“ú@ç—tŒ§¬“cŽs
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2025
é‹ÊŒ§Šá‰È‹³ˆçu‰‰‰ï
—ߘa7”N10ŒŽ26“ú@é‹ÊŒ§‚³‚¢‚½‚ÜŽs
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2025
é‹ÊŒ§Šá‰È‹³ˆçu‰‰‰ï
—ߘa7”N10ŒŽ26“ú@é‹ÊŒ§‚³‚¢‚½‚ÜŽs
îà‘º@‰ÀO
гŽÒƒtƒ@[ƒXƒg‚ð”O“ª‚É“ü‚ꂽ“œ”A•aŠá‡•¹Ç‚ɑ΂·‚éŗǂ̎¡—Ãí—ª‚ð‚ß‚´‚µ‚Ä
–L’†ŽsˆãŽt‰ïŠá‰Èˆã‰ïŠwpŒ¤‹†‰ï
—ߘa7”N11ŒŽ1“ú@‘åã•{–L’†Žs
гŽÒƒtƒ@[ƒXƒg‚ð”O“ª‚É“ü‚ꂽ“œ”A•aŠá‡•¹Ç‚ɑ΂·‚éŗǂ̎¡—Ãí—ª‚ð‚ß‚´‚µ‚Ä
–L’†ŽsˆãŽt‰ïŠá‰Èˆã‰ïŠwpŒ¤‹†‰ï
—ߘa7”N11ŒŽ1“ú@‘åã•{–L’†Žs
ˆî’J@‘å
—ΓàáŽèpŽ¡—Ãup to date 2025
ROCKƒJƒ“ƒtƒ@ƒŒƒ“ƒX in Ž ‰ê
—ߘa7”N11ŒŽ6“ú@Ž ‰êŒ§‘å’ÃŽs
—ΓàáŽèpŽ¡—Ãup to date 2025
ROCKƒJƒ“ƒtƒ@ƒŒƒ“ƒX in Ž ‰ê
—ߘa7”N11ŒŽ6“ú@Ž ‰êŒ§‘å’ÃŽs
ˆî’J@‘å
—Γàá‚Ì–ò•¨Ž¡—Ã@‚Ç‚¤‘±‚¯‚éH
ƒAƒCƒ‰ƒ~ƒh”z‡Œœ‘÷«“_Šá‰t@””„5Žü”N‹L”OƒZƒ~ƒi[
‘æ3‰ñ@‰ðàI—ΓàᎡ—ẪRƒc‚ƃ|ƒCƒ“ƒg
—ߘa7”N11ŒŽ7“ú@•ŸˆäŽs‚©‚ç‘S‘Web”zM
—Γàá‚Ì–ò•¨Ž¡—Ã@‚Ç‚¤‘±‚¯‚éH
ƒAƒCƒ‰ƒ~ƒh”z‡Œœ‘÷«“_Šá‰t@””„5Žü”N‹L”OƒZƒ~ƒi[
‘æ3‰ñ@‰ðàI—ΓàᎡ—ẪRƒc‚ƃ|ƒCƒ“ƒg
—ߘa7”N11ŒŽ7“ú@•ŸˆäŽs‚©‚ç‘S‘Web”zM
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2025
‘æ23‰ñŒ§“òŠá‰È—Õ°ƒtƒH[ƒ‰ƒ€
—ߘa7”N11ŒŽ8“ú@•ºŒÉŒ§“òèŽs
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2025
‘æ23‰ñŒ§“òŠá‰È—Õ°ƒtƒH[ƒ‰ƒ€
—ߘa7”N11ŒŽ8“ú@•ºŒÉŒ§“òèŽs
îà‘º@‰ÀO
DMEŽ¡—Âɶ‚©‚¹‚éƒoƒr[ƒXƒ‚‚Ì“Á«‚ðl‚¦‚é
“œ”A•a‚ðl‚¦‚é‰ï in ˆïé@`Šá‰È~“œ”A•a“à‰È`
—ߘa7”N11ŒŽ10“ú@ˆï錧“y‰YŽs
DMEŽ¡—Âɶ‚©‚¹‚éƒoƒr[ƒXƒ‚‚Ì“Á«‚ðl‚¦‚é
“œ”A•a‚ðl‚¦‚é‰ï in ˆïé@`Šá‰È~“œ”A•a“à‰È`
—ߘa7”N11ŒŽ10“ú@ˆï錧“y‰YŽs
ˆî’J@‘å
—Õ°¬Ñ‚©‚ç‚Ý‚½V‚µ‚¢‰Â”\«
—ΓàᎡ—ÂÌVÍ|ƒZƒ^ƒlƒI®“_Šá‰t0.002%‚Ì“oê\
—ߘa7”N11ŒŽ10“ú@•ŸˆäŽs‚©‚ç‘S‘Web”zM
—Õ°¬Ñ‚©‚ç‚Ý‚½V‚µ‚¢‰Â”\«
—ΓàᎡ—ÂÌVÍ|ƒZƒ^ƒlƒI®“_Šá‰t0.002%‚Ì“oê\
—ߘa7”N11ŒŽ10“ú@•ŸˆäŽs‚©‚ç‘S‘Web”zM
îà‘º@‰ÀO
“œ”A•a‚ÅŽ¸–¾‚µ‚È‚¢‚悤‚É`‹‚ß‚ç‚ê‚é“à‰È‚ÆŠá‰È‚̘AŒg`
‘æ6‰ñ@Ozone Ophthalmology Seminar
—ߘa7”N11ŒŽ27“ú@ˆ¤’mŒ§‚©‚çWeb”zM
“œ”A•a‚ÅŽ¸–¾‚µ‚È‚¢‚悤‚É`‹‚ß‚ç‚ê‚é“à‰È‚ÆŠá‰È‚̘AŒg`
‘æ6‰ñ@Ozone Ophthalmology Seminar
—ߘa7”N11ŒŽ27“ú@ˆ¤’mŒ§‚©‚çWeb”zM
ˆî’J@‘å
‘æ“ñ‘I‘ð–ò‚Æ‚µ‚Ă̔z‡Ü‚ðl‚¦‚é`‘S•ûˆÊŒ^”z‡“_Šá–òƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë`
Glaucoma Treatment OptionsƒZƒ~ƒi[
—ߘa7”N12ŒŽ5“ú@“Œ‹ž“s‚©‚ç‘S‘Web”zM
‘æ“ñ‘I‘ð–ò‚Æ‚µ‚Ă̔z‡Ü‚ðl‚¦‚é`‘S•ûˆÊŒ^”z‡“_Šá–òƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë`
Glaucoma Treatment OptionsƒZƒ~ƒi[
—ߘa7”N12ŒŽ5“ú@“Œ‹ž“s‚©‚ç‘S‘Web”zM
ˆî’J@‘å
—ΓàáŽèpŽ¡—Ãup to date
KOWA Ophthalmology Academy
—ߘa7”N12ŒŽ12“ú@“È–ØŒ§‰F“s‹{Žs
—ΓàáŽèpŽ¡—Ãup to date
KOWA Ophthalmology Academy
—ߘa7”N12ŒŽ12“ú@“È–ØŒ§‰F“s‹{Žs
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2025
‘æ119‰ñH“cŒ§Šá‰ÈW’k‰ï
—ߘa7”N12ŒŽ14“ú@H“cŽs
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2025
‘æ119‰ñH“cŒ§Šá‰ÈW’k‰ï
—ߘa7”N12ŒŽ14“ú@H“cŽs
ˆî’J@‘å
‚܂Ƃ߂ĉðàI—Γàá“_Šá–ò2026
‘æ5‰ñGR‚̉ï
—ߘa8”N2ŒŽ14“ú@ŽRŒûŒ§Žü“ìŽs
‚܂Ƃ߂ĉðàI—Γàá“_Šá–ò2026
‘æ5‰ñGR‚̉ï
—ߘa8”N2ŒŽ14“ú@ŽRŒûŒ§Žü“ìŽs
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2026
Šò•ŒŒ§Šá‰Èˆã‰ï¶ŠU‹³ˆçuK‰ï
—ߘa8”N2ŒŽ15“ú@Šò•ŒŽs
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2026
Šò•ŒŒ§Šá‰Èˆã‰ï¶ŠU‹³ˆçuK‰ï
—ߘa8”N2ŒŽ15“ú@Šò•ŒŽs
îà‘º@‰ÀO
DMEŽ¡—Âɶ‚©‚¹‚éƒoƒr[ƒXƒ‚‚Ì“Á«
DME Expert Web Seminar
—ߘa8”N2ŒŽ18“ú@Web”zM
DMEŽ¡—Âɶ‚©‚¹‚éƒoƒr[ƒXƒ‚‚Ì“Á«
DME Expert Web Seminar
—ߘa8”N2ŒŽ18“ú@Web”zM
ˆî’J@‘å
‘±”—Γàá‚ÌŽèp‚Í‚±‚¤‚·‚é‚ñ‚¾I
‘æ20‰ñ‹ž‘åŠá‰È@Focus on Glaucoma
—ߘa8”N3ŒŽ6“ú@•ŸˆäŽs‚©‚狞“sŽs‚ÖWeb”zM
‘±”—Γàá‚ÌŽèp‚Í‚±‚¤‚·‚é‚ñ‚¾I
‘æ20‰ñ‹ž‘åŠá‰È@Focus on Glaucoma
—ߘa8”N3ŒŽ6“ú@•ŸˆäŽs‚©‚狞“sŽs‚ÖWeb”zM
ˆî’J@‘å
y‚ä‚Á‚‚è‰ðàz—Γàá“_Šá–ò2026
‘æ10‰ñ‚ЂƂ݃lƒbƒg‚̉ï
—ߘa8”N3ŒŽ21“ú@–¼ŒÃ‰®Žs
y‚ä‚Á‚‚è‰ðàz—Γàá“_Šá–ò2026
‘æ10‰ñ‚ЂƂ݃lƒbƒg‚̉ï
—ߘa8”N3ŒŽ21“ú@–¼ŒÃ‰®Žs
—F“cÊ…AŠâ핌’‘¾˜YAˆî’J‘å
ŒŒŠÇV¶—Γàá‚ɑ΂·‚é—ΓàáŽèp‚ÌŽ¡—ìÑ
‘æ354‰ñ‹à‘òŠá‰ÈW’k‰ï@
—ߘa7”N4ŒŽ6“ú@‹à‘òŽs
ŒŒŠÇV¶—Γàá‚ɑ΂·‚é—ΓàáŽèp‚ÌŽ¡—ìÑ
‘æ354‰ñ‹à‘òŠá‰ÈW’k‰ï@
—ߘa7”N4ŒŽ6“ú@‹à‘òŽs
îà‘º‰ÀOAáÁ“c˜Ð‹GAŽR“c—Y‹MAˆî’J‘å
‹ÇŠ«DME‚ɑ΂·‚é’¼ÚƒŒ[ƒU[‚Ì‘O‚É‚ÍRVEGFŽ¡—·‚é‚ׂ«‚©H
‘æ5‰ñ’áNP–Ô–ŒƒŒ[ƒU[‚̉ï
—ߘa7”N4ŒŽ17“ú@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
‹ÇŠ«DME‚ɑ΂·‚é’¼ÚƒŒ[ƒU[‚Ì‘O‚É‚ÍRVEGFŽ¡—·‚é‚ׂ«‚©H
‘æ5‰ñ’áNP–Ô–ŒƒŒ[ƒU[‚̉ï
—ߘa7”N4ŒŽ17“ú@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
‘哈GK
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éRVEGF—Ö@ŠJŽnŒã‚ÌŒŒ“œƒRƒ“ƒgƒ[ƒ‹
‘æ9‰ñ–k—¤4‘åŠwŠá‰È‡“¯Œ¤‹†‰ï
—ߘa7”N5ŒŽ30“ú@‹à‘òŽs
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éRVEGF—Ö@ŠJŽnŒã‚ÌŒŒ“œƒRƒ“ƒgƒ[ƒ‹
‘æ9‰ñ–k—¤4‘åŠwŠá‰È‡“¯Œ¤‹†‰ï
—ߘa7”N5ŒŽ30“ú@‹à‘òŽs
Ÿ”öÊ…AŠâ핌’‘¾˜YAˆî’J‘å
ŒŒŠÇV¶—Γàá‚ɑ΂·‚éƒoƒ‹ƒxƒ‹ƒg‚ƃA[ƒƒh‚ÌŽèp¬Ñ”äŠr
‘æ91‰ñ•xŽRŠá‰ÈW’k‰ï
—ߘa7”N6ŒŽ29“ú@•xŽRŽs
ŒŒŠÇV¶—Γàá‚ɑ΂·‚éƒoƒ‹ƒxƒ‹ƒg‚ƃA[ƒƒh‚ÌŽèp¬Ñ”äŠr
‘æ91‰ñ•xŽRŠá‰ÈW’k‰ï
—ߘa7”N6ŒŽ29“ú@•xŽRŽs
¼‘ºŒ’‘å
—Γàá”z‡“_Šá‰t“_ŠáŒã‚É‚¨‚¯‚éŠá‹…‚ÌŒõŠw“IŽ¿‚Ì•]‰¿F–³ìˆ×‰»“ñdŽÕ•ÁƒNƒƒXƒI[ƒo[ŽŽŒ±
‘æ10‰ñ AGTS‚̉ï
—ߘa7”N7ŒŽ4-5“ú@å‘äŽs
—Γàá”z‡“_Šá‰t“_ŠáŒã‚É‚¨‚¯‚éŠá‹…‚ÌŒõŠw“IŽ¿‚Ì•]‰¿F–³ìˆ×‰»“ñdŽÕ•ÁƒNƒƒXƒI[ƒo[ŽŽŒ±
‘æ10‰ñ AGTS‚̉ï
—ߘa7”N7ŒŽ4-5“ú@å‘äŽs
—é–Ø—z•½AŽR“c—Y‹MA‚‘º‰ÀOAˆî’J‘å
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éƒtƒ@ƒŠƒVƒ}ƒu“Š—^Œã‚ÌŽc‘¶•‚Žî‚É‚¨‚¯‚é–Ñ׌ŒŠÇᎂ̉ðÍ
‘æ81‰ñ•ŸˆäŒ§Šá‰ÈW’k‰ï
—ߘa7”N8ŒŽ30“ú@•ŸˆäŽs
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éƒtƒ@ƒŠƒVƒ}ƒu“Š—^Œã‚ÌŽc‘¶•‚Žî‚É‚¨‚¯‚é–Ñ׌ŒŠÇᎂ̉ðÍ
‘æ81‰ñ•ŸˆäŒ§Šá‰ÈW’k‰ï
—ߘa7”N8ŒŽ30“ú@•ŸˆäŽs
Ÿ”öÊ…AŠâ핌’‘¾˜YAˆî’J‘å
ŒŒŠÇV¶—Γàá‚ɑ΂·‚éƒoƒ‹ƒxƒ‹ƒg‚ƃA[ƒƒh‚ÌŽèp¬Ñ”äŠr
‘æ45‰ñ‹à‘òˆã‰È‘åŠwŠá‰ÈŒ¤‹†‰ï
—ߘa7”N11ŒŽ9“ú@‹à‘òŽs
ŒŒŠÇV¶—Γàá‚ɑ΂·‚éƒoƒ‹ƒxƒ‹ƒg‚ƃA[ƒƒh‚ÌŽèp¬Ñ”äŠr
‘æ45‰ñ‹à‘òˆã‰È‘åŠwŠá‰ÈŒ¤‹†‰ï
—ߘa7”N11ŒŽ9“ú@‹à‘òŽs
”ª“c@‘ñ–ç
CO‚É‚æ‚镟ˆä‘åŠw‚̃[ƒrƒWƒ‡ƒ“ƒPƒA‚ÌŽæ‚è‘g‚Ý
•ŸˆäŒ§ƒ[ƒrƒWƒ‡ƒ“ƒPƒAƒZƒ~ƒi[
—ߘa7”N11ŒŽ28“ú@•ŸˆäŽs
CO‚É‚æ‚镟ˆä‘åŠw‚̃[ƒrƒWƒ‡ƒ“ƒPƒA‚ÌŽæ‚è‘g‚Ý
•ŸˆäŒ§ƒ[ƒrƒWƒ‡ƒ“ƒPƒAƒZƒ~ƒi[
—ߘa7”N11ŒŽ28“ú@•ŸˆäŽs
“cŒû—D‘¾AŽR“c—Y‹MA‚‘º‰ÀOAˆî’J‘åAJ-CREST group
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éÉŽq‘ÌŽèp‚Ì—LŒø«‚ÉŠÖ‚·‚鑽Ž{Ý•]‰¿
‘æ92‰ñ•xŽRŠá‰ÈW’k‰ï@
—ߘa7”N11ŒŽ30“ú@•xŽRŽs
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éÉŽq‘ÌŽèp‚Ì—LŒø«‚ÉŠÖ‚·‚鑽Ž{Ý•]‰¿
‘æ92‰ñ•xŽRŠá‰ÈW’k‰ï@
—ߘa7”N11ŒŽ30“ú@•xŽRŽs
“cŒû—D‘¾AŽR“c—Y‹MA‚‘º‰ÀOAˆî’J‘åAJ-CREST group
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éÉŽq‘ÌŽèp‚Ì—LŒø«‚ÉŠÖ‚·‚鑽Ž{Ý•]‰¿
‘æ355‰ñ‹à‘òŠá‰ÈW’k‰ï@
—ߘa7”N12ŒŽ14“ú@‹à‘òŽs
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éÉŽq‘ÌŽèp‚Ì—LŒø«‚ÉŠÖ‚·‚鑽Ž{Ý•]‰¿
‘æ355‰ñ‹à‘òŠá‰ÈW’k‰ï@
—ߘa7”N12ŒŽ14“ú@‹à‘òŽs
“cŒû—D‘¾
ÉŽq‘Ì“à’ŽË‚Ç‚¤‚µ‚Ä‚éH
‘æ82‰ñ•ŸˆäŒ§Šá‰ÈW’k‰ï
—ߘa8”N1ŒŽ10“ú@ƒzƒeƒ‹ƒtƒWƒ^•Ÿˆä
ÉŽq‘Ì“à’ŽË‚Ç‚¤‚µ‚Ä‚éH
‘æ82‰ñ•ŸˆäŒ§Šá‰ÈW’k‰ï
—ߘa8”N1ŒŽ10“ú@ƒzƒeƒ‹ƒtƒWƒ^•Ÿˆä
‰ß‹Ž‚Ì‹ÆÑ
Šw‰ï”•\@2025
Šw‰ï”•\@2024
Šw‰ï”•\@2023
Šw‰ï”•\@2022
Šw‰ï”•\@2021
Šw‰ï”•\@2020
Šw‰ï”•\@2019
Šw‰ï”•\@2018
Šw‰ï”•\@2017
Šw‰ï”•\@2016
Šw‰ï”•\@2015
Šw‰ï”•\@2014
Šw‰ï”•\@2013
Šw‰ï”•\@2012





![“ü‹Ç‚ðŠó–]‚·‚éŠF—l‚Ö](../../images/global_05.png)

